Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of age

Vaccine

Volumn 33, Issue 12, 2015, Pages 1499-1505

  Li, Xiaoming ^a   Zhang, Jane H ^b   Betts, Robert F ^c   Morrison, Vicki A ^d   Xu, Ruifeng ^a   Itzler, Robbin F ^a   Acosta, Camilo J ^a   Dasbach, Erik J ^a   Pellissier, James M ^a   Johnson, Gary R ^b   Chan, Ivan S F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Concurrent age effect; Durability; Herpes zoster; Poisson regression; Time effect; Vaccine efficacy; Zoster vaccine

Indexed keywords

VARICELLA ZOSTER VACCINE; VACCINE;

ADULT; AGE DISTRIBUTION; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; VACCINATION; AGED; AGING; FEMALE; IMMUNOLOGY; MALE; POISSON DISTRIBUTION; REGRESSION ANALYSIS; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; POISSON DISTRIBUTION; REGRESSION ANALYSIS; TIME FACTORS; VACCINATION; VACCINE POTENCY;

EID: 84924438472     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.039     Document Type: Article

References (16)

1. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a mew hypothesis. Proc R Soc Med 1965, 58:9-20.
2. Choo P.W., Donahue J.G., Manson J.E., Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995, 172:706-712.
3. Insinga R.P., Itzler R.F., Pellissier J.M., Saddier P., Nikas A.A. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005, 20:748-753.
4. Yawn B.P., Saddier P., Wollan P.C., St Sauver J.L., Kurland M.J., Sy L.S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82:1341-1349. (Erratum in: Mayo Clin Proc 2008;83:255).
5. Harpaz R., Ortega-Sanchez I.R., Seward J.F. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57:1-30.
6. Pellissier J.M., Brisson M., Levin M.J. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007, 25:8326-8337.
7. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.
8. Bilcke J., Ogunjimi B., Hulstaert F., Van Damme P., Hens N., Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice. Vaccine 2012, 30:2795-2800.
9. Schmader K.E., Oxman M.N., Levin M.J., Johnson G., Zhang J.H., Betts R., et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012, 55:1320-1328.
10. ® 9. 2 User's Guide 2009, Cary, NC. Second Edition.
11. Cameron A.C., Trivedi P.K. Regression Analysis of Count Data 1998, Cambridge University Press, Cambridge. UK.
12. Edmunds W.J., Brisson M., Rose J.D. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001, 19:3076-3090.
13. Hornberger J., Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006, 145:317-325.
14. Rothberg M.B., Virapongse A., Smith K.J. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007, 44:1280-1288.
15. Brisson M., Pellissier J.M., Camden S., Quach C., De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccine 2008, 4:238-245.
16. van Hoek A.J., Gay N., Melegaro A., Opstelten W., Edmunds W.J. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009, 27:1454-1467.